ArticleOncotarget2017

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.

Isabel Arrillaga-Romany et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.